Prostate Cancer Screening Guidelines

Age-Based Recommendations

The American College of Physicians recommends that screening discussions should begin at age 50 for average-risk men with at least 10-year life expectancy 2
African American men should begin PSA screening discussions earlier at age 45 due to higher risk of aggressive disease 3
Men with a family history of prostate cancer should start discussions at age 45 3
Men with multiple first-degree relatives diagnosed with prostate cancer before age 65 should begin screening discussions at age 40 3
Screening should not be performed in men over age 70 or those with life expectancy less than 10-15 years 2

A single elevated PSA level should not prompt immediate prostate biopsy and should be verified by a second measurement 1
Decision to proceed with prostate biopsy should consider multiple factors including DRE findings, ethnicity, age, comorbidities, PSA values, free/total PSA ratio, previous biopsy history, and patient preferences 1
Baseline PSA testing at age 40-45 may help establish future risk stratification and identify men at higher risk of developing significant prostate cancer 3

Population-based screening in men aged 55-69 years may prevent approximately 1.3 deaths from prostate cancer per 1,000 men screened over 13 years 4
PSA screening can reduce prostate cancer mortality by 21% (29% when adjusted for non-compliance) according to the European screening trial 1
However, 781 men need to be invited for screening and 27 patients need to be treated to prevent one death from prostate cancer 1
Harms of screening include false-positive results, psychological distress, overdiagnosis of indolent cancers, and complications from subsequent treatment 4

Multi-parametric MRI is recommended before repeat biopsy to improve diagnostic accuracy 1
Transrectal ultrasound-guided prostate biopsy should be performed under antibiotic cover and local anesthesia, with a minimum of 10-12 cores obtained 1
PSA levels can be affected by medications (finasteride, dutasteride) and recent activities (vigorous exercise, ejaculation within 2 days) 4
The extent of involvement of each biopsy core and the Gleason grades should be reported 1

Starting screening too late may miss opportunities to identify aggressive cancers when still curable 3
Not accounting for risk factors (race, family history) when determining screening initiation age 3
Continuing screening beyond age 70 in men with limited life expectancy increases harms without clear benefit 2
Failing to have informed discussions about the benefits and limitations of PSA screening 3
Proceeding to biopsy based on a single elevated PSA without confirmation 1

The American College of Physicians recommends against screening in men under 50, over 69, or with life expectancy less than 10-15 years 2
The European Society for Medical Oncology does not recommend population-based PSA screening but acknowledges that screening reduces prostate cancer mortality at the expense of overdiagnosis 1